Fig 2: ZNF92 expression and function.a Immunohistochemical stain of formalin fixed paraffin embedded sections probed with ZNF92 antibody. The normal breast demonstrates two subgroups of nuclear ZNF92-positive and ZNF92-negative cells (left panel, scale bar = 20 uM). In some breast cancers nearly all tumor cells are ZNF92-positive (middle panel) and other tumors are entirely ZNF92-negative (right panel, scale bar = 100 uM). b Immunofluorescent staining of HDAC7 (red), ZNF92 (green) and nuclear DAPI (blue) in BT20 cells. The merged panel demonstrates the co-expression of HDAC7 and ZNF92 in the same nuclei. The brightness of the entire digital image was increased in the single channel panels to visualize the lower cytoplasmic staining and the individual color channels were adjusted in the merged image for clarity. The uncropped and unprocessed images are provided in Supplementary Fig. 13. c Western blot analysis of ZNF92 protein expression in matched pairs of BPLER/HMLER 2, 3 and 4. d Western blot analysis of ZNF92 protein after siRNA knock-down of ZNF92 expression (ZNF92 si) in three independent BPLER lines compared to control siRNA (ct si). The uncropped and unprocessed western blot images are provided in Supplementary Fig. 14. e Bar graphs showing that siRNA knock-down of ZNF92 expression (ZNF92 si) results in statistically significant reduction (*) in cell numbers in all three independent BPLER lines compared to control siRNA (ct si). f–h KM-plot survival analysis of the 29 genes in ET-125 with a ZNF92 binding site, demonstrating a correlation between high expression of ZNF92 targets and poor overall survival in all breast cancers (HR = 1.6, p = 0.0002) and high-grade (grade 3) breast cancer (HR = 2.1, p = 0.003), as well as relapse free survival in triple-negative breast carcinoma (HR = 2.4, p = 0003) The relative hazard ratios (HR) were computed using Cox proportional hazard regression analysis. See Supplementary Fig. 11 for overall and relapse free survival for other breast cancer cohorts including HER2, Basal-like, Luminal-B, and chemotherapy treated cohorts.